Entero Therapeutics Crecimiento futuro

Future controles de criterios 0/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Entero Therapeutics de 3.3% y 79.8% respectivamente, mientras que el BPA crecerá en un 49.3% al año.

Información clave

3.3%

Tasa de crecimiento de los beneficios

49.3%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	24.2%
Tasa de crecimiento de los ingresos	79.8%
Rentabilidad financiera futura	n/a
Cobertura de analistas	Low
Última actualización	20 May 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

First Wave BioPharma announces pricing of $6.0 million public offering

Oct 07

First Wave BioPharma extends selloff after announcing strategic shift

Sep 19

First Wave stock slips ~21% on plans for amended FDA application for enzyme adrulipase

Sep 07

First Wave BioPharma announces 1-for-30 reverse stock split

Aug 25

First Wave BioPharma to raise capital in convertible preferred stocks offering

Jul 15

First Wave BioPharma Set For New Growth Trajectory With GI Pipeline Expansion De-Risking The Investment

Oct 19

AzurRx BioPharma, First Wave Bio in niclosamide licensing pact for gastrointestinal infections

Jan 04

AzurRx up 9% on advancement of mid-stage study of MS1819 in CF patients

Nov 30

Is AzurRx BioPharma (NASDAQ:AZRX) In A Good Position To Invest In Growth?

Nov 19

Previsiones de crecimiento de beneficios e ingresos

NasdaqCM:ENTO - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	N/A	-42	N/A	N/A	1
12/31/2025	N/A	-32	N/A	N/A	1
12/31/2024	N/A	-11	N/A	N/A	2
3/31/2024	N/A	-6	-14	-13	N/A
12/31/2023	N/A	-16	-13	-12	N/A
9/30/2023	N/A	-16	-15	-15	N/A
6/30/2023	N/A	-8	-15	-15	N/A
3/31/2023	N/A	-9	-17	-17	N/A
12/31/2022	N/A	-15	-22	-22	N/A
9/30/2022	N/A	-22	-33	-23	N/A
6/30/2022	N/A	-57	-44	-34	N/A
3/31/2022	N/A	-65	-45	-35	N/A
12/31/2021	N/A	-85	-43	-32	N/A
9/30/2021	N/A	-92	-32	-32	N/A
6/30/2021	N/A	-74	-19	-19	N/A
3/31/2021	N/A	-66	-15	-15	N/A
12/31/2020	N/A	-42	-11	-11	N/A
9/30/2020	N/A	-25	-9	-9	N/A
6/30/2020	N/A	-15	-10	-10	N/A
3/31/2020	N/A	-16	-13	-13	N/A
12/31/2019	N/A	-15	-14	-14	N/A
9/30/2019	N/A	-18	-14	-14	N/A
6/30/2019	N/A	-16	-13	-13	N/A
3/31/2019	N/A	-15	-12	-11	N/A
12/31/2018	N/A	-14	-11	-11	N/A
9/30/2018	N/A	-12	-10	-10	N/A
6/30/2018	N/A	-13	-9	-9	N/A
3/31/2018	N/A	-12	-8	-8	N/A
12/31/2017	N/A	-11	N/A	-7	N/A
9/30/2017	N/A	-14	N/A	-7	N/A
6/30/2017	N/A	-14	N/A	-7	N/A
3/31/2017	N/A	-15	N/A	-5	N/A
12/31/2016	N/A	-15	N/A	-5	N/A
9/30/2016	N/A	-10	N/A	-3	N/A
6/30/2016	N/A	-8	N/A	-4	N/A
3/31/2016	N/A	-7	N/A	-4	N/A
12/31/2015	N/A	-6	N/A	-4	N/A
9/30/2015	N/A	-6	N/A	-4	N/A
6/30/2015	N/A	-5	N/A	-3	N/A
3/31/2015	N/A	-3	N/A	-2	N/A
12/31/2014	N/A	-2	N/A	-1	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que ENTO siga sin ser rentable en los próximos 3 años.

Beneficios vs. Mercado: Se prevé que ENTO siga sin ser rentable en los próximos 3 años.

Beneficios de alto crecimiento: Se prevé que ENTO siga sin ser rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que ENTO no tenga ingresos el año que viene.

Ingresos de alto crecimiento: Se prevé que ENTO no tenga ingresos el año que viene.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de FWBI se prevé que sea elevada dentro de 3 años.

Entero Therapeutics Crecimiento futuro

Future controles de criterios 0/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Price target decreased to US$9.00

Price target decreased to US$20.00

Price target decreased to US$25.00

No longer forecast to breakeven

Price target raised to US$4.10

Recent updates

First Wave BioPharma, Inc.(NasdaqGM:ENTO) dropped from NASDAQ Composite Index

First Wave BioPharma, Inc. has filed a Follow-on Equity Offering in the amount of $0.9882 million.

First Wave BioPharma, Inc. (NasdaqCM:FWBI) completed the acquisition of ImmunogenX, LLC for approximately $3 million.

First Wave BioPharma, Inc. (NasdaqCM:FWBI) completed the acquisition of ImmunogenX, LLC for approximator $3 million.

First Wave BioPharma, Inc. has filed a Follow-on Equity Offering in the amount of $4.000006 million.

First Wave BioPharma, Inc. has withdrawn its Follow-on Equity Offering.

First Wave BioPharma, Inc. (NasdaqCM:FWBI) signed a non-binding term sheet to acquire ImmunogenX, LLC.

First Wave BioPharma, Inc. has filed a Follow-on Equity Offering.

First Wave Biopharma, Inc. Receives Written Notice from the Listing Qualifications Department of the Nasdaq Stock Market

First Wave BioPharma Receives Notice from Nasdaq Regarding Non-Compliance with Minimum Bid Price Requirement for Continued Listing on The Nasdaq Capital Market

First Wave BioPharma Receives Non-Compliance Notice from Nasdaq Regarding Non-Compliance with the Minimum Stockholders’ Equity Requirement Under Listing Rule 5550(b)(1)

First Wave BioPharma, Inc. Announces Initial Topline Results from Phase 2 Span Clinical Trial Investigating Enhanced Adrulipase Formulation

New major risk - Share price stability

First Wave Biopharma Completes Patient Screening for Phase 2 Span Adrulipase Clinical Trial in Cystic Fibrosis

First Wave BioPharma Regains Compliance with Nasdaq’s Minimum Bid Price Requirement

First Wave BioPharma Announces First Patient Screened for Phase 2 SPAN Adrulipase Trial in Cystic Fibrosis

First Wave BioPharma Announces Initiation of Phase 2 Trial Investigating Enhanced Adrulipase Formulation in Exocrine Pancreatic Insufficiency in Patients with Cystic Fibrosis

First Wave BioPharma, Inc. Announces Expansion of Adrulipase Intellectual Property Portfolio

First Wave BioPharma, Inc. Provides Update on IND Filing for Phase 2 Trial of Enhanced Microgranule Formulation of Adrulipase for Exocrine Pancreatic Insufficiency

First Wave BioPharma Receives A Deficiency Notice from the Listing Qualifications Staff of Nasdaq Regarding Minimum Bid Price

First Wave BioPharma, Inc. Announces Initial Clinical Sites for its Phase 2 Trial of Enhanced Microgranule Delivery Formulation of Adrulipase

First Wave BioPharma Files Investigational New Drug Application for Enhanced Microgranule Delivery Formulation of Adrulipase

First Wave BioPharma, Inc. Presents Research Demonstrating Benefits of Improved Adrulipase Drug Delivery Formulation at AAPS 2022 PharmSci 360

First Wave BioPharma, Inc. has completed a Follow-on Equity Offering in the amount of $6.000001 million.

First Wave BioPharma announces pricing of $6.0 million public offering

First Wave BioPharma, Inc. Provides Update on Clinical Programs

First Wave BioPharma extends selloff after announcing strategic shift

First Wave BioPharma, Inc. Finalizes Selection of Adrulipase Microgranule Drug Delivery Formulation

First Wave stock slips ~21% on plans for amended FDA application for enzyme adrulipase

First Wave BioPharma Announces Reverse Stock Split

First Wave BioPharma announces 1-for-30 reverse stock split

Price target decreased to US$9.00

High number of new and inexperienced directors

First Wave BioPharma, Inc., Annual General Meeting, Aug 25, 2022

First Wave BioPharma to raise capital in convertible preferred stocks offering

First Wave Biopharma, Inc Announces Resignation from the Board of Directors

First Wave BioPharma, Inc. announced delayed 10-Q filing

First Wave BioPharma, Inc. Appoints David Hoffman as Member of the Board

Price target decreased to US$20.00

High number of new and inexperienced directors

James Pennington Announces His Intention to Retire as Chief Medical Officer of First Wave BioPharma, Inc

First Wave BioPharma, Inc. Files U.S. and PCT Patent Applications for Niclosamide in Long-Haul COVID-19

First Wave Biopharma, Inc. Announce Chief Financial Officer Changes

First Wave BioPharma, Inc. Provides Update on Adrulipase (FW-EPI) Clinical Program

First Wave BioPharma, Inc. Completes Enrollment for Part 2 of RESERVOIR Phase 2 Trial Evaluating FW-COV in COVID-19-Related GI Infections

High number of new directors

First Wave BioPharma Receives A Letter from the Listing Qualifications Department of the Nasdaq Stock Market LLC

First Wave BioPharma Set For New Growth Trajectory With GI Pipeline Expansion De-Risking The Investment

First Wave BioPharma Begins Patient Screening for Phase 2b Clinical Trial Evaluating Niclosamide in Patients with Ulcerative Proctitis and Ulcerative Proctosigmoiditis

Price target decreased to US$25.00

AzurRx BioPharma, Inc. (NasdaqCM:AZRX) agreed to acquire First Wave Bio, Inc. for $230 million.

AzurRx BioPharma, Inc. Announces Positive Results from Independent Data Monitoring Committee Review of Safety Data from Part 1 of RESERVOIR Phase 2 Clinical Trial of Niclosamide for the Treatment of COVID-19 Gastrointestinal Infections

AzurRx BioPharma Submits an Investigational New Drug Application for Niclosamide as Treatment for Grade 1 and Grade 2 Immune Checkpoint Inhibitor-Associated Colitis

No longer forecast to breakeven

AzurRx BioPharma, Inc. Announces Positive Topline Data for Phase 2 MS1819 Combination Therapy Trial in Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency

AzurRx BioPharma Inc Completes Initial Cohort Enrollment into Part 1 of its RESERVOIR Phase 2 Clinical Trial of Niclosamide for the Treatment of COVID-19 Gastrointestinal Infections

Azurrx Biopharma, Inc. Adds New Clinical Trial Sites in Ukraine for Phase 2 Reservoir Clinical Trial of Niclosamide for the Treatment of Covid-19 Gastrointestinal Infections

AzurRx BioPharma Receives A Letter from the Listing Qualifications Staff of the Nasdaq Stock Market

AzurRx BioPharma, Inc. Doses First Patient in Phase 2 Clinical Trial of Niclosamide for the Treatment of Covid-19 Gastrointestinal Infections

AzurRx Biopharma doses first patient in mid-stage niclosamide COVID-19 study

AzurRx BioPharma, Inc. announced delayed 10-Q filing

AzurRx BioPharma, Inc. Announces Positive Interim Data in Phase 2 Clinical Trial of Ms1819 in Combination with Pert in the Treatment of Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency

AzurRx BioPharma: An Assessment

AzurRx BioPharma, Inc. Announces Completion of Enrollment in Phase 2B Option 2 Clinical Trial of Ms1819 in Cystic Fibrosis

AzurRx BioPharma, Inc. Announces Chairman Changes

Price target raised to US$4.10

AzurRx Biopharma Engages PPD to Manage Clinical Trial for Niclosamide as Treatment for COVID-19 Gastrointestinal Infections

AzurRx Officially A COVID-19 Play - The Right Dose For Your Portfolio

AzurRx BioPharma, Inc. Announces Completion of Enrollment in First Cohort of Phase 2b OPTION 2 Extension Study of MS1819

AzurRx BioPharma, Inc. Adds Two New Clinical Trial Sites in Europe for Phase 2b OPTION 2 Extension Study of MS1819 Immediate-Release Capsules in Cystic Fibrosis Patients